No quarterly revenue total was found in VICAPSYS LIFE SCIENCES, INC.'s SEC filings.
Vicapsys Life Sciences, Inc. (VICP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-235,507
+2.0% vs year-ago quarter
Operating cash flow
$-40,431
+62.4% vs year-ago quarter
Free cash flow
—
EPS
$-0.01
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
32.37M
-0.8% vs year-ago quarter
Net cash
$-9,290
Q4 FY2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VICP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Cumming, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1468639
- Former names
- SSGI, INC. (until Nov 7, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2024 Sep 30, 2024 |
Q2 FY2024 Jun 30, 2024 |
Q1 FY2024 Mar 31, 2024 |
Q4 FY2023 Dec 31, 2023 |
Q3 FY2023 Sep 30, 2023 |
|---|---|---|---|---|---|
| Operating income | -$198,862 | -$181,841 | -$204,255 | -$527,207 | -$175,423 |
| Net income | -$235,507 | -$190,091 | -$327,072 | -$594,803 | -$240,340 |
| Diluted EPS | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.01 |
| Operating cash flow | -$40,431 | $6,166 | -$9,422 | -$82,054 | -$107,410 |
| Total assets | $89,569 | — | — | $39,656 | $208,486 |
| Stockholders' equity | -$2.6M | -$2.4M | -$2.3M | -$1.9M | -$1.3M |
| Cash and investments | $89,569 | — | — | $9,422 | $53,532 |
| Total debt | — | $12,546 | $12,546 | $18,712 | $36,789 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jan 10, 2025 | Sep 30, 2024 |
| 10-Q | Quarterly report | Jan 10, 2025 | Jun 30, 2024 |
| 10-Q | Quarterly report | Jan 10, 2025 | Mar 31, 2024 |
| 10-K | Annual report | Oct 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, New debt
|
Dec 27, 2023 | Dec 26, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
All 92 Vicapsys Life Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.